European Rare Blood Disorders Platform (ENROL) (ENROL)

February 6, 2024 updated by: Hospital Universitari Vall d'Hebron Research Institute

ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare Hematological Diseases (RHDs). ENROL aims at avoiding fragmentation of data by promoting the standards for patient registries' interoperability released by the EU RD platform.

ENROL's principle is to maximize public benefit from data on RHDs opened up through the platform with the only restriction needed to guarantee patient rights and confidentiality, in agreement with EU regulations for cross-border sharing of personal data.

Accordingly, ENROL will map the EU-level demographics, survival rates, diagnosis methods, genetic information, main clinical manifestations, and treatments in order to obtain epidemiological figures and identify trial cohorts for basic and clinical research. To this aim, ENROL will connect and facilitate the upgrading of existing RHD registries, while promoting the building of new ones when / where lacking. Target-driven actions will be carried out in collaboration with EURORDIS for educating patients and families about the benefits of enrolment in such registries, including different cultural and linguistic strategies.

The standardized collection and monitoring of disease-specific healthcare outcomes through the ENROL user-friendly platform will determine how specialized care is delivered, where are the gaps in diagnosis, care, or treatment and where best to allocate financial, technical, or human resources.

Moreover, it will allow for promoting research, especially for those issues that remain unanswered or sub-optimally addressed by the scientific community; furthermore, it will allow promoting clinical trials for new drugs. ENROL will enable the generation of evidence for better healthcare for RHD patients in the EU as the ultimate goal.

ENROL officially started on 1st June 2020 with a duration of 36 months. ENROL is co-funded by the Health Programme of the European Union under the call for proposals HP-PJ-2019 on Rare disease registries for the European Reference Networks. GA number 947670

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Study Title:

European Rare Blood Disorders Platform (ENROL)

Study Objectives:

The European Rare Blood Disorders Platform (ENROL) is conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet), as the umbrella platform for both new and already existing registries on Rare Hematological Diseases (RHDs) avoiding fragmentation of data by promoting the interoperability standards for patient registries.

ENROL aims at mapping demographics, diagnosis methods, genetic data, main clinical manifestations and treatments at the EU level by enabling the connection, upgrading and building of EU patients registries in line with EU data protection and interoperability standards with the following major objectives:

Promoting research: allowing the identification of patient cohorts to facilitate the development of collaborative projects on basic and clinical research on RHD Epidemiological surveillance: pooling of available data on registries and databases across European countries to monitor trends and provide essential epidemiologic information on RHD while enabling the generation of evidence for the optimum allocation of resources and health planning For this, ENROL will obtain comparable EU data for RHD on demographics, survival rates, diagnosis methods, genetic information, main clinical manifestations and treatments by promoting the interoperability standards for patient registries in line with the European Platform on Rare Disease Registration (EU RD Platform). ENROL is officially endorsed by the European Hematology Association (EHA).

Methodology:

Data on patients with RHDs will be collected retrospectively and prospectively at the time of inclusion on the registry and at 12-month intervals for all registered patients.

The ENROL strategy for data gathering combines the exhaustiveness of data collection at EU level for health planning and epidemiological purposes, with a higher level of RHD data granularity for promoting research and identification of patients' cohorts.

Accordingly, the platform has been designed to integrate data from any available sources, including Healthcare providers (ERN-EuroBloodNet members / Other EU healthcare providers) and EU/national/local existing registries. Data entry is also allowed with different levels of granularity to pursue ENROL aims, including counts/aggregated level data to increase data exhaustiveness at the EU level required for the epidemiological surveillance, and pseudonymised individual level data to promote research and facilitate the identification of trial groups.

As defined in GDPR Art. 26, a Joint Controllership is being established where the institutions conforming the Consortium (HUVH/VHIR, ULB/ERASME, CING and AP-HP) for the jointly determine the purposes and means of processing and assume equal responsibilities in terms of data protection.

Data processing and analyses will be conducted in various sub studies, after every 1000 patients included in the European Registry and/or at the end of each interim follow-up period (every 12 months).

Disease coverage

The study population consist of both males and females aged from 0 to 100 year old diagnosed as RHD according to ORPHANET classification (ORPHA 97992), including myeloid and lymphoid tumors (ORPHA 68347), rare anaemia disorders (ORPHA 108997), rare coagulation disorders (ORPHA 98429), and polycythemia (ORPHA 98427), and further complemented with rare hereditary hemochromatosis (ORPHA220489), included in the disease scope of ERN-EuroBloodNet following a request from well-established patient groups and experts.

Accordingly, ENROL disease coverage results in more than 450 different entities with differential clinical and etiological features i.e. oncological vs non-oncological, hereditary vs acquired, or significant difference frequency, among others, which can be classified into the following disease groups:

RAD: Inherited Rare Anaemia Disorders, including inherited Bone Marrow Failures BMF: Acquired Bone Marrow Failures Bleeding: Rare bleeding-coagulation disorders and related diseases HH-Iron: Hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis Myeloid: Myeloid malignancies Lymphoid: Lymphoid malignancies

ENROL dataset has been conceived in a bottom-up design for ensuring the capture of the common elements for rare diseases in line with the EU recommendations and with the EU RD platform, and the key features common for the whole spectrum for RHDs. Furthermore, the latest level can be stepped up for the definition of domain specific elements that support the in-depth analysis.

In the spirit of ENROL aims to promote the connection and linkage of available data sources and the creation of new registries where lacking. ENROL promotes collaborations for supporting the a) upgrade the existing registries and b) create new European registries in compliance with the standards of interoperability and ENROL policy. Collaboration agreements will be in place for the transfer of a subset of the data elements gathered to ENROL.

Study Duration and funding

An extensive recruitment period and follow-up, as well as geographical coverage, is desirable for long-term sustainability of the European Epidemiological Platform. Accordingly, ENROL has not an expected ending date but continue the pooling and processing of data for an indeterminate period of time.

ENROL is co-funded by the Health Programme of the European Union under the call for proposals HP-PJ-2019 on Rare disease registries for the European Reference Networks. GA number 947670.

Study Type

Observational

Enrollment (Estimated)

37090

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: María del Mar Manú Pereira, PhD
  • Phone Number: +34934893000
  • Email: mar.manu@vhir.org

Study Contact Backup

Study Locations

  • Spain
    • Catalunya
      • Barcelona, Catalunya, Spain, 08035
        • Recruiting
        • María del Mar
        • Contact:
        • Contact:
          • María del Mar Mañú Pereira, Biologist
          • Phone Number: 0034934893000
          • Email: mar.manu@vhir.org

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Patients with Rare Hematological Disease

Description

Inclusion Criteria:

  • Patients must meet all of the following criteria to be included in the ENROL Registry
  • Age from 0-100, both female and male
  • Diagnosed as RHDs according to ORPHANET classification
  • Able and willing to provide written informed consent (patient or legal representative for minors) if needed according to national legislation.

Exclusion Criteria:

  • Patients diagnosed as traits or trait conditions for other recessive RHDs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Inherited Rare Anaemia Disorders, including inherited Bone Marrow Failures
Patients with Inherited Rare Anemia Disorders, including inherited Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy
Acquired Bone Marrow Failures
Patients with Acquired Bone Marrow Failures, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy
Rare bleeding-coagulation disorders and related diseases
Patients with Rare bleeding-coagulation disorders and related diseases, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy
Hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis
Patients with hemochromatosis and other rare genetic disorders of iron metabolism and heme synthesis, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy
Myeloid malignancies
Patients with Myeloid malignancies, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy
Lymphoid malignancies
Patients with lymphoid malignancies, stratified by gender, age, and/or variants/types if applicable.
Other: Collection of clinical and laboratory data from EHR.
Observational sutdy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demography and epidemiology
Time Frame: 15 years
To collect and to describe demographics and epidemiological data of any type of RHDs.
15 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Collaborators

ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases

Investigators

  • Principal Investigator: Petros Kountouris, PhD, Cyprus Institute of Neurology and Genetics (CING)
  • Principal Investigator: María del Mar Manú Pereira, PhD, Vall d'Hebron Institut de Recerca / University Hospital Vall d'Hebron (VHIR / HUVH)
  • Principal Investigator: Béatrice Gulbis, MD, Hôpital ERASME / ULB (ERASME_ULB)
  • Principal Investigator: Pierre Fenaux, MD, Assistance Publique - Hôpitaux de Paris (AP-HP)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2022

Primary Completion (Estimated)

July 1, 2037

Study Completion (Estimated)

July 1, 2037

Study Registration Dates

First Submitted

December 4, 2023

First Submitted That Met QC Criteria

February 6, 2024

First Posted (Estimated)

February 9, 2024

Study Record Updates

Last Update Posted (Estimated)

February 9, 2024

Last Update Submitted That Met QC Criteria

February 6, 2024

Last Verified

December 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PR(AMI)294/2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leukemia

Clinical Trials on Collection of clinical and laboratory data from EHR.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe